American Journal of Cardiology
Volume 105, Issue 6 , Pages 819-825 , 15 March 2010

Outcomes in Diabetic Versus Nondiabetic Patients Who Present With Acute Myocardial Infarction and Are Treated With Drug-Eluting Stents

Received 21 September 2009 ,Revised 8 November 2009 ,Accepted 8 November 2009.

References 

  1. In:  Ruderman N,  Williamson J,  Brownlee M editor. Hyperglycemia, Diabetes, and Vascular Disease. New York: Oxford University Press; 1992;p. 21–29
  2. Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med. 2004;164:2273–2279
  3. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008;118:2277–2285
  4. Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol. 2008;101:1560–1566
  5. Lee MS, Jurewitz D, Zimmer R, Pessegueiro A, Bhatia R, Currier J, et al. Impact of diabetes and acute coronary syndrome on survival in patients treated with drug-eluting stents. Catheter Cardiovasc Interv. 2008;72:909–914
  6. Zhang Q, Shen J, Zhang RY, Qiu JP, Lu JD, Zhang Y, et al. Outcomes after primary coronary intervention with drug-eluting stent implantation in diabetic patients with acute ST elevation myocardial infarction. Chin Med J [Engl]. 2007;120:1862–1867
  7. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J. 2008;156:44–56
  8. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359:1330–1342
  9. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105–1113
  10. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093–1104
  11. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706–2713
  12. Novack V, Tsyvine D, Cohen DJ, Pencina M, Dubin J, Dehghani H, et al. Multivessel drug-eluting stenting and impact of diabetes mellitus—a report from the EVENT registry. Catheter Cardiovasc Interv. 2008;73:874–880
  13. Rozenman Y, Sapoznikov D, Gotsman MS. Restenosis and progression of coronary disease after balloon angioplasty in patients with diabetes mellitus. Clin Cardiol. 2000;23:890–894
  14. Mathew V, Holmes DR. Outcomes in diabetics undergoing revascularization: the long and the short of it. J Am Coll Cardiol. 2002;40:424–427
  15. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004;109:476–480
  16. Mathew V, Wilson SH, Barsness GW, Frye RL, Lennon R, Holmes DR. Comparative outcomes of percutaneous coronary interventions in diabetics vs non-diabetics with prior coronary artery bypass grafting. Eur Heart J. 2002;23:1456–1464
  17. Goyal A, Mehta SR, Gerstein HC, Díaz R, Afzal R, Xavier D, et al. Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. Am Heart J. 2009;157:763–770
  18. Li L, Guo Y, Guo L, Gao W. The predictive value of admission glucose for the prognosis of AMI post primary percutaneous coronary intervention. Cardiovasc Revasc Med. 2006;7:99
  19. Iijima R, Mehilli J, Schomig A, Kasrati A. Drug eluting stents versus Bare metal stents in diabetic patients with acute myocardial infarction: a pooled analysis of individual patient data from 7 randomized trials. Rev Esp Cardiol. 2009;62:354–364
  20. Park DW, Park SW, Kima JS, Nam HJ, Lee JY, Kim GJ, et al. Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in Asian patients. Am J Cardiol. 2009;103:646–652
  21. Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, et al. Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study (The diabetes and drug eluting stent for LeFT main registry (D-DELFT)). Eurinterv. 2008;4:77–83
  22. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138–1145
  23. Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol. 2009;103:345–349
  24. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663–670
  25. Moss SC, Lightell D, Deichmann RE, Woods TC. Sera from patients with diabetes do not alter the effect of mammalian target of rapamycin inhibition on smooth muscle cell proliferation. J Cardiovasc Pharmacol. 2009;53:86–89
  26. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559
  27. Lemesle G, Bonello L, de Labriolle A, Maluenda G, Syed AI, Collins SD, et al. Prognostic value of hemoglobin A1c levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol. 2009;104:41–45
  28. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94:300–305
  29. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial. Am Heart J. 2008;155:215–223

PII: S0002-9149(09)02683-6

doi: 10.1016/j.amjcard.2009.11.010

American Journal of Cardiology
Volume 105, Issue 6 , Pages 819-825 , 15 March 2010

Article Tools

* Image Usage & Resolution